SCHEMBL1810388

SCHEMBL1810388

COc1ccc(-c2cc(C(=O)O)ccc2OC2CC(F)(F)C2)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 5/20 0.46
▸ PDE4A P27815 4/20 0.46
▸ PDE4C Q08493 4/20 0.46
▸ PDE4D Q08499 4/20 0.46
▸ PLG P00747 1/20 0.44
▸ PLAU P00749 1/20 0.44
▸ TTR P02766 1/20 0.43
▸ RARA P10276 2/20 0.43
▸ RARB P10826 2/20 0.43
▸ RARG P13631 2/20 0.43
▸ LMNA P02545 4/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NR1I2 O75469 1/20 0.41
▸ PGR P06401 1/20 0.41
▸ HSPD1 P10809 1/20 0.41
▸ GOT1 P17174 1/20 0.41
▸ GLRA1 P23415 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ HSPE1 P61604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1810988 0.90 KMT2A (0.43) PDE4BPDE4APDE4CPDE4DLMNA
SCHEMBL13464508 0.84 LPAR1 (0.51) PDE4BPDE4APDE4CPDE4DLMNA
SCHEMBL6845266 0.82 LPAR1 (0.45) PDE4BPDE4APDE4CPDE4DLMNA
SCHEMBL1815336 0.82 LPAR1 (0.45) PDE4BPDE4APDE4CPDE4DLMNA
SCHEMBL1815334 0.82 LPAR1 (0.45) PDE4BPDE4APDE4CPDE4DLMNA
SCHEMBL16544895 0.81 CA12 (0.59) PDE4BPDE4APDE4CPDE4DTTR
SCHEMBL1811907 0.80 LPAR1 (0.40) PDE4BPDE4APDE4CPDE4DLMNA
SCHEMBL2744369 0.76 LMNA (0.52) PDE4BPLGPLAUTTRLMNA
SCHEMBL24214139 0.75 HRH3 (0.44) PDE4BPDE4APDE4CPDE4DLMNA
SCHEMBL1810796 0.75 TTR (0.48) PDE4BPLGPLAUTTRRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496556-B1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2018-12-26 — — EP disclosed
US-9018383-B2 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2015-04-28 — — US disclosed
US-20140088158-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2014-03-27 — — US disclosed
US-8618304-B2 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2013-12-31 — — US disclosed
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-10-18 — — US disclosed
EP-2496556-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-09-12 — — EP disclosed
WO-2011053948-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 PDE4B 399/4885PDE4A 316/4885PDE4C 396/4885
US-20140088158-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 PDE4B 399/4885PDE4A 316/4885PDE4C 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback